Table 2.
HDACi combination therapies under investigation are recruiting for relapsed/refractory cutaneous T-cell lymphomas.
| Combination trials | Mechanism of action | Phase | ClinicalTrial.gov ID |
|---|---|---|---|
| Romidepsin + Brentuximab vedotin |
HDAC inhibitor + antibody-drug conjugate | I | NCT02616965 |
| Romidepsin + lenalidomide | HDAC inhibitor+ Immunomodulatory drugs | II | NCT02232516 |
| Pralatrexate + Romidepsin | HDAC inhibitor + antifolate | I/II | NCT01947140 |
| Romidepsin + Parsaclisib | HDAC inhibitor + PI3Kδ inhibitor |
I | NCT04774068 |
| Romidepsin + Pembrolizumab | HDAC inhibitor + Immunotherapy | I/II | NCT03278782 |
| Romidepsin | Romidepsin maintenance after Allogeneic Stem Cell Transplantation | I | NCT02512497 |
| Romidepsin + 5-Azacitadine | hypomethylation agent + HDAC inhibitor | I/II | NCT01998035 |
| Romidepsin, CC-486 Dexamethasone,Lenalidomide |
HDAC inhibitor + Immunomodulatory drugs | I | NCT04447027 |